The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering blunt force compared to penetrating trauma: a systematic review protocol.
作者信息
Bonanno Laura, Badeaux Jennifer, Devlin Raymond
机构信息
Louisiana State University Health Sciences Center School of Nursing, the Louisiana Center for Evidence-Based Nursing at LSUHSC School of Nursing: an Affiliate Center of the Joanna Briggs Institute, Louisiana, New Orleans, United States of America.
出版信息
JBI Database System Rev Implement Rep. 2015 Mar 12;13(2):125-35. doi: 10.11124/jbisrir-2015-1744.
PMID:26447038
Abstract
摘要
相似文献
1
The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering blunt force compared to penetrating trauma: a systematic review protocol.
JBI Database System Rev Implement Rep. 2015 Mar 12;13(2):125-35. doi: 10.11124/jbisrir-2015-1744.
2
The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering from blunt force trauma compared with penetrating trauma: a systematic review.
JBI Database System Rev Implement Rep. 2016 Mar;14(3):116-38. doi: 10.11124/JBISRIR-2016-2063.
3
Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.
J Trauma. 2010 Sep;69(3):489-500. doi: 10.1097/TA.0b013e3181edf36e.
4
The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage.
Transfusion. 2009 Dec;49 Suppl 5:240S-7S. doi: 10.1111/j.1537-2995.2008.01987.x.
5
Factor VIIa (recombinant) for acute traumatic hemorrhage.
Am J Health Syst Pharm. 2008 Sep 1;65(17):1616-23. doi: 10.2146/ajhp080008.
6
Recombinant activated factor VII for acute intracerebral hemorrhage.
N Engl J Med. 2005 May 19;352(20):2133-4; author reply 2133-4.
7
The use of new procoagulants in blunt and penetrating trauma.
Curr Opin Anaesthesiol. 2019 Apr;32(2):200-205. doi: 10.1097/ACO.0000000000000696.
8
Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding.
Crit Care. 2006;10(4):R104. doi: 10.1186/cc4977.
9
Should recombinant factor VIIa be used for the treatment of patients with severe blunt trauma?
Br J Hosp Med (Lond). 2007 Dec;68(12):688. doi: 10.12968/hmed.2007.68.12.688.
10
A response to 'the use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma.
Anaesthesia. 2005 Nov;60(11):1156-7; author reply 1157. doi: 10.1111/j.1365-2044.2005.04422.x.
Zotero 插件